PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 2013 January; 87(2): 1200–1210.
PMCID: PMC3554066

Human Papillomavirus E7 Induces Rereplication in Response to DNA Damage

Abstract

Human papillomavirus (HPV) infection is necessary but not sufficient for cervical carcinogenesis. Genomic instability caused by HPV allows cells to acquire additional mutations required for malignant transformation. Genomic instability in the form of polyploidy has been demonstrated to play an important role in cervical carcinogenesis. We have recently found that HPV-16 E7 oncogene induces polyploidy in response to DNA damage; however, the mechanism is not known. Here we present evidence demonstrating that HPV-16 E7-expressing cells have an intact G2 checkpoint. Upon DNA damage, HPV-16 E7-expressing cells arrest at the G2 checkpoint and then undergo rereplication, a process of successive rounds of host DNA replication without entering mitosis. Interestingly, the DNA replication initiation factor Cdt1, whose uncontrolled expression induces rereplication in human cancer cells, is upregulated in E7-expressing cells. Moreover, downregulation of Cdt1 impairs the ability of E7 to induce rereplication. These results demonstrate an important role for Cdt1 in HPV E7-induced rereplication and shed light on mechanisms by which HPV induces genomic instability.

INTRODUCTION

Genomic instability is a hallmark of cancer progression (1). Genomic instability in the form of polyploidy, wherein cells have more than two sets of chromosomes, has been implicated as a causal factor in tumorigenesis (2, 3). Tetraploidy in basal keratinocytes has been found in low-grade squamous intraepithelial lesions of the cervix infected with high-risk but not low-risk human papillomavirus (HPV) types (4). Significantly, it was demonstrated that tetraploidy occurred as an early event during cervical carcinogenesis and predisposed cells to aneuploidy that is consistently observed in all cancers (5). Polyploidy can be formed via rereplication, a process in which origins fire more than once within a single S phase, or endoreduplication, in which multiple S phases occur without an intervening mitosis (6). Endoreduplication can occur in G2, early mitosis, or S phase. In the literature, the term rereplication has often been used for both rereplication and endoreduplication (6). To reduce confusion, we will use the term rereplication for DNA rereplication that occurs within the same interphase and endoreduplication for DNA rereplication that occurs after cells enter into mitosis. Rereplication can lead not only to polyploidy but also to gene amplification (7), DNA fragmentation (8), DNA breaks (9), and cellular DNA damage response (reference 10 and references therein).

Papillomaviruses are small DNA viruses that replicate in the stratified layers of skin and mucosa. Human papillomaviruses (HPVs) can be classified as either high or low risk depending on their clinical associations. The high-risk HPV types, such as HPV-16 and HPV-18, are commonly associated with lesions that can progress to high-grade cervical intraepithelial neoplasia and cervical carcinoma (for a review, see reference 11). The transforming properties of high-risk HPVs reside primarily in the E6 and E7 oncogenes, and the sustained expression of these genes appears to be essential for the maintenance of the transformed state of HPV-positive cells (reference 12 and references therein). E6 and E7 from high-risk HPV types induce genomic instability that occurs early in preneoplastic lesions, when the viral genome still persists in an episomal state (13, 14). The ability of the high-risk HPV E7 protein to bind and promote the degradation of pRb has been suggested as a mechanism by which HPV oncogenes promote tumor formation, although E7 also has functions independent of inactivating pRb (reviewed in reference 13).

Cell cycle progression is regulated at several checkpoints whose defects contribute to genomic instability (15). The checkpoints in eukaryotic cells include the G1 checkpoint, the G2 checkpoint, the spindle assembly checkpoint, and the postmitotic checkpoint (16). The cell cycle is driven mainly by cyclins and cyclin-dependent kinases (Cdks) (17) and is partly controlled by p53 and pRb (17, 18). Although it is well documented that HPV E7 abrogates the G1 checkpoint (13), its effect on the G2 checkpoint is not as clear. In primary human keratinocytes (PHKs) expressing HPV-16 E7, an intact G2 checkpoint was implicated after treatment with doxorubicin (Adriamycin) (19). However, interpretation of this observation is complicated by the fact that doxorubicin inhibits topoisomerase II that triggers a decatenation checkpoint (20) in addition to inducing DNA breaks (21). In contrast, mouse NIH 3T3 cells expressing HPV E7 were thought to be unable to maintain a G2 arrest after doxorubicin treatment (22). In response to 60Co, the G2 checkpoint is maintained in human fibroblasts expressing HPV-16 E7 (23). On the other hand, following hydroxyurea treatment, more HPV-16 E7-expressing PHKs than control cells were found in mitosis (24).

We have recently demonstrated that in response to microtubule disruption, E6 and E7 induced polyploidy through endoreduplication, a process including cell arrest at the spindle checkpoint, mitotic slippage, and abrogation of the postmitotic checkpoint (25, 26). Induction of polyploidy by HPV E7 in mouse NIH 3T3 cells treated with doxorubicin was proposed by Polager and Ginsberg to be a result of endoreduplication, though evidence was not provided (22). The mechanism by which E6 or E7 induces polyploidy in response to DNA damage therefore remains unknown.

In the present study, we examined the effect of HPV-16 E7 on the G2 checkpoint in PHKs and explored the mechanism by which E7 induces polyploidy in response to DNA damage. We show that HPV E7-expressing cells have an intact G2 checkpoint. In response to DNA damage, HPV E7 induces rereplication. We also demonstrate a role for the DNA replication initiation factor Cdt1 in E7-induced rereplication.

MATERIALS AND METHODS

Cell culture.

PHKs and cervical epithelial cells (CEs) were obtained from the University of Massachusetts Hospital. Cervical epithelial cells containing the HPV-16 genome (CE-HPV) (27) were provided by Aloysius Klingelhutz, University of Iowa. These cells were cultured on mitomycin C-treated J2-3T3 feeder cells in E medium composed of three parts Dulbecco's modified Eagle medium (DMEM) and one part Ham's F12 medium plus 5% fetal bovine serum (FBS), with all supplements as previously described (26). The human telomerase reverse transcriptase-expressing human retinal pigment epithelium cell line (RPE1) was maintained in a 1:1 dilution of DMEM-Ham's F-12 medium plus 10% FBS.

PHKs and RPE1 cells expressing HPV-16 E7 were established using the pBabe retroviral system. Early-passage PHKs (within 3 passages) were used for infection. Retroviruses encoding HPV-16 E7 or vector were produced by transfection of PA317 or LinXA packaging cells. After transfection, retrovirus was collected in E medium or RPE1 medium. The PHKs or RPE1 cells were infected with retroviruses in 8 μg/ml hexadimethrine bromide (Polybrene) for 6 h. Cells were allowed to recover for 24 h and then selected with 1.25 μg/ml puromycin (PHKs) or 12.5 μg/ml puromycin (RPE1) for 3 to 6 days. Populations of infected cells were pooled and expanded. To ensure that a high percentage of cells will express E7 or contain the retroviral vector, PHKs and RPE1-derived cell lines were maintained in puromycin (0.5 μg/ml and 6.5 μg/ml, respectively) and used within 10 passages. Parental PHKs do not proliferate well after long-term culture with such puromycin concentrations.

For UV treatment, the RPE1-Babe or E7 cells were rinsed twice with phosphate-buffered saline (PBS) and resuspended in PBS during UV exposures. Dishes were uncovered and exposed to UV irradiation using the germicidal UV lamp in a tissue culture hood for 1 min and then released to regular medium and incubated for 48 h.

Immunoblotting.

Protein extraction was prepared in lysis buffer (10 mM Tris [pH 7.4], 1% SDS, 1.0 mM sodium orthovanadate). The protein concentration was measured by the bicinchoninic acid (BCA) protein assay reagent (Pierce) and confirmed by Coomassie blue staining of membranes after blotting. Equal amounts of protein from each cell lysate were separated in an SDS polyacrylamide gel (PAGE) and transferred onto a polyvinylidene difluoride (PVDF) membrane. Membranes were blotted with antibodies against Cdt1 (a gift from Anita Dutta, Millipore, number 071383, and Santa Cruz Biotechnology, H-300, sc-28262), Cdc25c (Cell Signaling; number 4688s), p-Cdc25c (Cell Signaling; number 4901s), β-tubulin (Sigma; T-4026), and β-actin (Sigma; A-2066). For E7 detection, whole-cell extracts (150 μg) in ML buffer (300 mM NaCl, 0.5% Nonidet P-40 [NP-40], 20 mM Tris-HCl [pH 8.0], 1 mM EDTA) were separated by SDS-PAGE, transferred onto a PVDF membrane, and subsequently probed with a mixture of 8C9 (Zymed/Invitrogen; number 28-0006, at a 1:150 dilution) and ED17 (Santa Cruz Biotechnology; sc-6981, at a 1:200 dilution). Horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit were used as secondary antibodies. β-actin or β-tubulin was used to indicate the loading amount of total proteins. ImageJ (NIH) was used to quantify gel images.

Immunofluorescence.

For phospho-histone H2AX staining, 1.5 × 105 cells were seeded onto a 60-mm dish and grown on coverslips. The following day, cells were treated with bleomycin (5 μg/ml). During 48 h of treatment, bleomycin was replenished in 24 h. Cells were fixed with 95% ethanol/5% acetic acid for 5 min at room temperature and blocked with 3% bovine serum albumin (BSA)/Tris-buffered saline (TBS) buffer for 30 min at room temperature. Cells were then incubated with antibody against phospho-histone H2AX (Millipore; 05-636) for 1 h at a 1:100 dilution, followed by incubation with a fluorescein isothiocyanate (FITC)-labeled anti-mouse secondary antibody. Cells were washed in PBS, counterstained with 4,5-diamidino-2-phenylindole dihydrochloride (DAPI; Vector Laboratories), and analyzed with the Olympus BX51 epifluorescence microscope equipped with a multiband filter set. Two-color images were overlaid using the Nikon NIS-Elements BR 3.10 imaging software.

Flow cytometry.

For cell cycle and polyploidy analysis, asynchronous cultures of PHKs and RPE1 cells expressing HPV E7 or vector alone were treated with PBS or bleomycin (Alexis Biochemicals; 5 μg/ml in PBS). For CE-HPV or the control, the cells were treated with 200 ng/ml bleomycin. For cisplatin treatment, cells were incubated for 6 h with 50 μM cisplatin (Sigma), washed with PBS, and incubated with cisplatin-free medium for 42 h. Forty-eight hours later, after the feeder cells were removed, cells were collected, fixed in 70% ethanol overnight, resuspended in PBS, stained in propidium iodide (PI) (50 μg/ml in PBS; Sigma) staining solution supplemented with 70 μg/ml RNase A (Sigma), and analyzed by flow cytometry. Cell cycle analysis was done using FlowJo software (Tree Star, Inc., Ashland, OR). For a nocodazole trapping assay, cells were first treated with 10 μg/ml bleomycin for 12 h and then incubated with bleomycin (10 μg/ml) plus nocodazole (50 ng/ml) for an additional 24 h. For the mitotic marker phospho-histone H3 (P-HH3) staining, cells were fixed in 70% ethanol, permeabilized in 0.25% Triton X-100, stained with 0.5 μg of the rat anti-phospho-histone H3 (anti-PHH3) immunoglobulin G 2a (IgG2a) (Sigma), followed by staining with fluorescein isothiocyanate (FITC)-conjugated anti-rat IgG2a (BD Biosciences), and counterstained with PBS-PI-RNase A.

For the bromodeoxyuridine (BrdU) labeling experiment, asynchronous cultures of cells were treated with PBS or bleomycin. BrdU (final, 20 μM) was added to the medium 2 h before collection of cells. Cells were then harvested and fixed in 70% ethanol overnight. The cells were permeabilized with 2 N HCl-0.5% Triton X-100, neutralized with 0.1 M sodium tetraborate, stained with monoclonal anti-BrdU (BD Biosciences), followed by anti-mouse IgG F(ab)2-FITC (Sigma) staining, and counterstained with PBS-PI-RNase A.

RNA interference (RNAi).

Small interfering RNA (siRNA) oligonucleotides were purchased from Dharmacon, Inc. The siRNA duplexes were the nonsilencing control siRNA sense strand (5-UUCUCCGAACGUGUCACGU-3′), Cdt1-siRNA001 (5′-AACGUGGAUGAAGUACCCGAC-3′) (sense strand, described in reference 28), and Cdt1-siRNA002 (5′-CCUACGUCAAGCUGGACAA-3′) (sense strand, described in reference 29). For polyploidy analysis, 1.2 × 105 cells were seeded onto a 60-mm dish the day before transfection. Cells were transfected with a final concentration of 20 nM siRNA per target gene using Lipofectamine 2000 transfection reagent according to the manufacturer's instructions (Invitrogen). The next day after transfection, cells were treated with 4 μg/ml bleomycin, incubated for an additional 36 to 48 h, and then harvested 72 h posttransfection. For protein knockdown analysis, cells were seeded onto a 60-mm dish the day before siRNA transfection. Seventy-two hours after transfection, cells were harvested and specific protein levels were analyzed by immunoblot. For the BrdU labeling experiment, RPE1-E7 cells were transfected with 20 nM siRNA. Thirty-six hours later, the cells were treated with bleomycin (4 μg/ml) for an additional 36 h. BrdU (final, 20 μM) was added to the medium at 2 h before collection of cells. Cells were then stained and analyzed as described above.

Statistical analysis.

All data are shown as means and standard deviations (SDs). The Student t test was used to compare the differences between means. Significance was set at a P value of <0.05.

RESULTS

PHKs expressing HPV-16 E7 have an intact G2 checkpoint in response to DNA damage.

We have shown previously that upon DNA damage, PHKs expressing HPV-16 E7 or both E6 and E7 bypassed the G1 checkpoint and accumulated at the G2/M phase with an increase in cells with more than 4C DNA content (26). Upon treatment with bleomycin, a radiomimetic (30), newly prepared PHKs from a different individual reproducibly demonstrated E7-induced polyploidy (Fig. 1A). Similar results were obtained in RPE1 cells expressing HPV-16 E7 (Fig. 1B). Expression of E7 in both cell types was demonstrated by a Western blot (data not shown). Significantly, cervical epithelial cells containing the HPV-16 genome also became polyploid after bleomycin treatment (Fig. 1C). Cisplatin, another DNA damage agent that has been widely used to treat cervical cancer, also induced polyploidy of HPV E7-expressing RPE1 cells (Fig. 1D). The treatment with the DNA damage agent is biologically relevant, as both E6 and E7 oncogenes from high-risk HPV types induce DNA damage and genomic instability (3133). DNA damage may also result from spontaneous decay, replication errors, and cellular metabolism (34). Consistent with this notion, spontaneous polyploidization in PHKs expressing E7 was observed (Fig. 1A). Although no significant spontaneous polyploidy was seen in early-passage RPE1 cells expressing E7 (Fig. 1B), over an extended period of culture, a small but statistically significant increase in the percentage of polyploidy in these cells has been found (25). Bleomycin treatment enhanced the extent of DNA damage (Fig. 1E).

Fig 1
HPV-16 E7 induces polyploidy upon DNA damage. Asynchronous cultures of cells were treated with PBS, bleomycin, or cisplatin. Forty-eight hours later, cells were collected, fixed, stained with PI, and analyzed by flow cytometry. (A) PHKs expressing HPV-16 ...

Next, we extended our studies to determine the integrity of the G2 checkpoint in early-passage cells expressing E7. Cells in the G2 phase and in mitosis normally have similar DNA contents of 4C. To distinguish between these two cell populations, we used the mitotic specific marker P-HH3 (35) to determine which cells were in mitosis. Using P-HH3 as a marker may underestimate the number of mitotic cells due to sensitivity and tendency of mitotic cells to detach from the culture dish. The trypsinization and removal steps for feeder cells before collection of PHKs would further reduce the number of mitotic cells. For this concern, we emphasize the relative numbers of mitotic cells with and without DNA damage. After bleomycin treatment, PHKs expressing E7, like vector control cells, showed a reduced number of cells expressing P-HH3, demonstrating that these cells with 4C DNA content are mainly at G2 and not in mitosis (Fig. 2A). This indicates that the G2 checkpoint in these cells is intact. Similar results were obtained in E7-expressing RPE1 cells (Fig. 2B), cervical epithelial cells containing the HPV-16 genome (Fig. 2C), and RPE1-E7 cells treated with cisplatin (Fig. 2D). We also used DAPI to stain cells in mitosis. We counted a total of approximately two thousand regularly cultured RPE1 cells and identified 1.7% and 1.9% mitotic cells (as indicated by cells with condensed chromosomes and a lack of a nuclear membrane) in vector- and E7-expressing cells, respectively. Upon bleomycin treatment, however, no apparent DAPI-positive cells can be identified from more than one thousand vector- or E7-expressing RPE1 cells (data not shown). These results are consistent with what was observed when P-HH3 was used as the mitotic marker.

Fig 2
HPV-16 E7-expressing cells have an intact G2 checkpoint upon DNA damage. Asynchronous cultures of cells were treated with bleomycin, cisplatin, or PBS. Cells were collected, fixed, stained with rat anti-PHH3 IgG2a and FITC-conjugated anti-Rat IgG2a, counterstained ...

To provide more evidence that the bleomycin-treated cells are in G2 instead of mitosis, we examined the protein phosphatase Cdc25c, a protein responsible for dephosphorylation and activation of Cdk1 (3638). During interphase, Cdc25C is phosphorylated on Ser216 [phospho-Cdc25c (Ser216)] (39). During the transition from interphase to mitosis, Cdc25c becomes hyperphosphorylated (40). As shown in Fig. 2E, upon bleomycin treatment, while undetectable in the vector control cells, Cdc25c in E7-expressing RPE1 cells is phosphorylated on Ser216 in a form similar to those in asynchronous cells but different from those in mitosis (hyperphosphorylated, as demonstrated by the appearance of an upper band in nocodazole-treated cells using antibody against total Cdc25c). The weak band detected by the antibody specific to phospho-Cdc25c (Ser216) after nocodazole treatment suggests that a small percentage of cells are still in interphase, while the hyperphosphorylated band suggests that some phospho-Cdc25c (Ser216) may persist during mitosis and can be further phosphorylated at additional amino acids. These results indicate that RPE1-E7 cells remain largely in interphase instead of mitosis after bleomycin treatment. In conjunction with results from flow cytometry analysis (Fig. 1B) that indicate that the majority of RPE1-E7 cells contains 4C DNA content, the evidence suggests that these cells are in the G2 stage of the cell cycle. Based on these results, we conclude that in HPV E7-expressing cells, while the G1 checkpoint is defective, the G2 checkpoint is largely intact in response to DNA damage.

HPV E7-expressing cells undergo rereplication upon DNA damage.

Since E7-expressing cells have an intact G2 checkpoint and polyploidy occurred without the cells entering mitosis, we conclude that endoreduplication is not the major mechanism for E7-expressing cells to become polyploid. However, it remains possible that a small percentage of cells expressing E7 can enter into mitosis after DNA damage and lead to endoreduplication. To test this possibility, we added nocodazole to trap cells that may have bypassed the G2 checkpoint in mitosis. Our previous studies have demonstrated that HPV E6 and E7 do not have much effect on the spindle checkpoint and that cells expressing E7 arrest in mitosis for an extended period of time (25). As shown in Fig. 3A, after addition of nocodazole following DNA damage, the percentage of P-HH3-positive cells is still very small (0.11%), indicating that few cells entered mitosis after bleomycin treatment. Furthermore, the percentage of polyploidy formed in PHKs expressing E7 after bleomycin treatment in the presence of nocodazole did not change significantly compared with that in PHKs treated with bleomycin alone, suggesting that endoreduplication does not contribute much to polyploidy formation under this experimental condition. These results suggest that rereplication is the major mechanism by which E7 induces polyploidy formation in response to DNA damage.

Fig 3
HPV-16 E7 induces DNA rereplication upon DNA damage. (A) Asynchronous cultures of PHK-E7 cells were treated with bleomycin (10 μg/ml) for 12 h. Nocodazole (50 ng/ml) was added, and cells were cultured for an additional 24 h. Cells were collected, ...

To confirm that polyploidy formation in E7-expressing cells is a result of DNA replication, we measured BrdU incorporation in E7-expressing cells. As shown in Fig. 3B, after 16 h of bleomycin treatment, increasing numbers of E7-expressing PHKs with >4C DNA content stained with BrdU and became polyploid, indicating that rereplication had occurred. Notably, a significant number (~5%) of E7-expressing PHKs underwent rereplication without bleomycin treatment, a finding which may be a result of DNA damage induced by E7. The number of cells with >4C DNA content continued to increase up to 48 h after DNA damage while the number of P-HH3-positive cells did not change significantly (data not shown). Similar results were observed in RPE1 cells expressing HPV-16 E7 and cervical epithelial cells containing the HPV-16 genome (Fig. 3B). Together with results shown in Fig. 3A, our results demonstrate that rereplication is the major mechanism by which E7 induces polyploidy formation in response to DNA damage.

The DNA replication initiating factor Cdt1 is upregulated in E7-expressing cells.

As an initial step toward understanding the mechanism by which E7 induces rereplication, we examined the expression of Cdt1, which is the only known mammalian gene that efficiently triggers rereplication when overexpressed in cancer cells (9, 41, 42). As shown in Fig. 4A, the steady-state level of Cdt1 was significantly increased (by more than 4-fold) in E7-expressing PHKs compared to that in the vector control PHKs. Notably, an extra band that is more evident in PHK-E7 cells was observed by using the antibody (Ab) from Santa Cruz (sc-28262, H-300) (Fig. 4A, upper panel). However, this band is absent in cervical epithelial cells containing the HPV-16 genome and RPE1 cells (Fig. 4A, lower panel) and it may represent a cell-type-specific posttranslational modification of Cdt1 in PHKs. Upregulation of Cdt1 protein also occurs in RPE1-E7 cells (Fig. 4A, lower panel). Also, while bleomycin treatment led to a reduction of Cdt1 in the vector control cells, no significant change in the steady-state level of Cdt1 was seen in RPE1-E7 cells (Fig. 4B). Consistent with what was observed previously (43), Cdt1 levels dropped after UV treatment in RPE1-Babe cells (Fig. 4B). Interestingly, unlike what was observed with bleomycin treatment, UV treatment reduced the steady-state level of Cdt1 in E7-expressing RPE1 cells, although the reduction is not as much as that in the vector control cells (Fig. 4B).

Fig 4
Upregulation of Cdt1 in E7-expressing cells. (A) Cdt1 levels in PHKs (upper panel) and RPE1 cells (lower panel) expressing E7 or vector were examined by Western blotting. β-actin was used as a loading control. CE-HPV cells (upper panel) were also ...

We also examined Cdt1 protein stability in E7-expressing RPE1 cells. Consistent with the steady-state level of Cdt1, the half-life of Cdt1 in E7-expressing cells is longer than that in the vector-containing cells (~3 h versus ~1 h) (Fig. 4C). The half-life of Cdt1 in the vector-containing RPE1 cells upon DNA damage was not able to be measured, as the steady-state level of Cdt1 in these cells was very low upon bleomycin treatment, even in the presence of MG132, the proteasome inhibitor (Fig. 4C). In contrast, upon bleomycin treatment, the half-life of Cdt1 in E7-expressing cells did not change significantly (Fig. 4C). These results demonstrate that Cdt1 expression in E7-expressing cells is regulated at the posttranslational level. Since Cdt1 is an E2F-regulated gene that is negatively regulated by pRb (44), it is expected that Cdt1 transcription should also be upregulated in E7-expressing cells.

Cdt1 plays an important role in E7-induced rereplication.

To confirm the role of Cdt1 in E7-induced rereplication, we used siRNAs targeting Cdt1. These siRNAs were previously demonstrated to downregulate Cdt1 expression after transfection into cultured cells (28, 29). Transfection of siRNAs targeting Cdt1 efficiently reduced the steady-state levels of Cdt1 in RPE1-E7 and RPE1-Babe cells (Fig. 5A). For RPE1-E7 cells, the Cdt1 levels were also reduced by siRNA after bleomycin treatment (Fig. 5A, lower panel). In one case (Cdt1-siRNA001), the level of Cdt1 was still higher than that in the vector control cells; in the other case (Cdt1-siRNA002), the level of Cdt1 was reduced to that in the vector control cells (Fig. 5A, upper panel). Therefore, knocking down of Cdt1 by these siRNAs should not disrupt normal DNA replication initiation. We then used these siRNAs to assess the role of Cdt1 in E7-induced rereplication. Notably, the percentage of polyploidy in siRNA-transfected RPE1 cells expressing E7 was lower than those shown in Fig. 1A (13% versus 26%), probably due to the toxicity of the transfection reagent. Nonetheless, knocking down Cdt1 by Cdt1-siRNA001 led to a statistically significant reduction in polyploidy formation in RPE1 cells expressing E7 after bleomycin treatment (Fig. 5B). Similar results were obtained using Cdt1-siRNA 002 (data not shown). Moreover, knocking down of Cdt1 by Cdt1-siRNA001 led to a significant reduction of BrdU incorporation for RPE1-E7 cells with >4C DNA content (Fig. 5C). These results demonstrate that upregulation of Cdt1 is important for E7 to induce rereplication and contributes to the polyploid formation in E7-expressing cells.

Fig 5
Downregulation of Cdt1 impairs the ability of E7 to induce rereplication. (A) RPE1-E7 and RPE1-Babe cells were transfected with Cdt1-siRNAs. Some dishes of RPE1-E7 cells were treated with bleomycin (4 μg/ml) for the final 36 h. Seventy-two hours ...

DISCUSSION

We have recently shown that in response to microtubule disruption, HPV E7 abrogates the postmitotic checkpoint to induce endoreduplication (25). In this study, we demonstrated that upon DNA damage, cells expressing HPV oncogene E7 did not arrest at the G1 checkpoint, likely due to G1 checkpoint abrogation as previously described (4547). However, E7 does not alleviate the G2 checkpoint. While being arrested at G2, cells expressing E7 induce rereplication. HPV E7 therefore induces polyploidy via different mechanisms in response to different insults. We also show that the DNA replication initiation factor Cdt1 is upregulated in E7-expressing cells and is important for E7-induced rereplication.

Compared with the G1 checkpoint, which is defective in HPV E7-expressing cells (4547), less attention has been paid to the effect of HPV on the G2 checkpoint. While some studies suggest that HPV E7 does not abrogate the G2 checkpoint in early-passage cells, several groups of investigators had different opinions. Specifically, mouse NIH 3T3 cells expressing HPV E7 were believed to be defective for the G2 checkpoint in response to doxorubicin treatment (22). However, the ability of E7-expressing cells to enter into mitosis was not examined in this study. Notably, upon hydroxyurea treatment, more HPV-16 E7-expressing PHKs than control cells were found in mitosis (24). It is likely that the G2 checkpoint in E7-expressing PHKs may respond differently to different types of DNA-damaging agents. However, it is evident that the percentage of E7-expressing cells entering mitosis in this case is relatively small (0.9%) while the percentage of cells in G2 upon hydroxyurea treatment is expected to increase significantly. Collectively, these data suggest that although a small number of E7-expressing cells can enter into mitosis in the presence of DNA damage, the G2 checkpoint in these cells is largely intact. The controversy between the previous studies and our current observation regarding the function of the G2 checkpoint can therefore be explained by differences in data interpretation as well as experimental conditions.

During the HPV life cycle, several mechanisms that arrest cells at the G2 checkpoint have been proposed. For example, the HPV-16 E4 protein prevents the nuclear entry of the mitotic cyclin/Cdk (48). In suprabasal cells, E7 expression induced cytoplasmic accumulation of cyclin B1 and Cdk1 with inactivating phosphorylation and G2 arrest following S phase reentry (31). Arresting cells at G2 may facilitate viral replication, as several viruses were found to replicate their genomes in the G2 phase (49). Interestingly, it was suggested that Cdt1 contributes to HIV Vpr-induced G2 arrest (50). On the other hand, activation of some of the host DNA replication machinery might be needed for viral DNA replication. In the case of HPV, whose productive life cycle is linked to epithelial differentiation, E7 establishes conditions permissive for viral DNA amplification (reference 31 and references therein). Having an intact G2 checkpoint and activation of the host DNA replication machinery, such as Cdt1, is therefore consistent with what is expected for a role of E7 in the viral life cycle. However, the E7 from the high-risk HPV types may also upregulate Cdt1 in the basal layer of stratified epithelia and induces the host genome instability that contributes to carcinogenesis. Future studies should examine the role of Cdt1 in HPV genome amplification and the ability of E7 from the low-risk HPV types to upregulate Cdt1.

Since Cdt1 is the only known mammalian gene that efficiently triggers rereplication when overexpressed (14, 41, 42), it is not surprising that Cdt1 is upregulated in E7-expressing cells and plays an important role in E7-induced rereplication. Notably, Cdt1 overexpression-induced rereplication was observed only in cancer cells previously; here, we show that E7 induces rereplication that is mediated by Cdt1 in primary and immortalized cells as well. Unexpectedly, the Cdt1 protein remains relatively stable in E7-expressing cells upon bleomycin treatment (Fig. 4C). Three E3 ubiquitin ligases, SCF-Skp2, APC/C, and DDB1-Cul4, have been identified to target Cdt1 for proteolysis (43, 5154). UV-dependent Cdt1 destruction is mediated by DDB1-Cul4 ubiquitin ligase, which appears to be functioning in E7-expressing cells (Fig. 4B). In PHKs expressing E6 and E7, the APC/C ubiquitin ligase complex was shown to be active (55). It is possible that the SCF-Skp2 ligase is somehow compromised in cells expressing E7. Consistent with this notion, in cervical cancers, the Skp2 ligase does not appear to be functioning (56). Interestingly, E7 was shown to bind Skp2 and was ubiquitinated by the SCF-Skp2 ligase (57). It remains to be determined whether the SCF-Skp2 ligase or some other as-yet-unidentified E3 ubiquitin ligases are indeed altered in E7-expressing cells. While we have demonstrated that Cdt1 expression in E7-expressing cells is regulated at posttranslational levels, this does not rule out the possibility that E7 also regulates Cdt1 expression at the transcriptional level. It is known that Cdt1 is an E2F-regulated gene that is negatively regulated by pRb (44). pRb degradation may therefore contribute to E7-induced Cdt1 upregulation and rereplication.

Although our data demonstrate that Cdt1 plays an important role in E7-induced rereplication, how DNA damage enhances rereplication in E7-expressing cells is still not clear, since the level of Cdt1 is not further increased in these cells upon DNA damage. A straightforward explanation for DNA damage-enhanced rereplication in E7-expressing cells is that the G2 arrest allows extra time for licensing of DNA replication to occur. However, merely extra time may not be sufficient for the initiation of rereplication, as DNA replication licensing factors are subjected to multiple regulations in the G2 phase (58). DNA damage in E7-expressing cells may inhibit cyclin A-Cdk1 activity and lead to an increased Cdt1 activity for licensing and therefore induces rereplication. It was observed that Cdt1 phosphorylation by cyclin A-dependent kinases reduces its affinity to DNA and that Cdk1 inactivation results in Cdt1 dephosphorylation and rebinding to chromatin/nuclear matrix (59). Consistent with this observation, Cdk1 inactivation in G2 phase promotes relicensing (60, 61). Alternatively, the level of binding affinity to Cdt1 by its inhibitory protein geminin might be reduced upon DNA damage in E7-expressing cells. Further studies are needed to test these possibilities.

ACKNOWLEDGMENTS

This work was supported by award R01CA119134 from the National Cancer Institute (NCI).

We thank Anindya Dutta for the Cdt1 antibody, Nick Rhind and Elliot Androphy for helpful suggestions, Sriramana Kanginakudra for reading the manuscript, and Aloysius Klingelhutz for cervical epithelial cells containing the HPV-16 genome.

Footnotes

Published ahead of print 14 November 2012

REFERENCES

1. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646–674. [PubMed]
2. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, Lazebnik Y. 2007. A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr. Biol. 17:431–437. [PubMed]
3. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. 2005. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437:1043–1047. [PubMed]
4. Giannoudis A, Herrington CS. 2000. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 89:1300–1307. [PubMed]
5. Olaharski AJ, Sotelo R, Solorza-Luna G, Gonsebatt ME, Guzman P, Mohar A, Eastmond DA. 2006. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis 27:337–343. [PubMed]
6. Porter AC. 2008. Preventing DNA over-replication: a Cdk perspective. Cell Div. 3:3. [PMC free article] [PubMed]
7. Mariani BD, Schimke RT. 1984. Gene amplification in a single cell cycle in Chinese hamster ovary cells. J. Biol. Chem. 259:1901–1910. [PubMed]
8. Davidson IF, Li A, Blow JJ. 2006. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol. Cell 24:433–443. [PMC free article] [PubMed]
9. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A. 2003. A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 11:997–1008. [PubMed]
10. Zhu W, Dutta A. 2006. An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication. Mol. Cell. Biol. 26:4601–4611. [PMC free article] [PubMed]
11. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342–350. [PubMed]
12. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A, DiPaolo JA. 1998. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc. Natl. Acad. Sci. U. S. A. 95:1189–1194. [PubMed]
13. Chen JJ. 2010. Genomic instability induced by human papillomavirus oncogenes. N. Am. J. Med. Sci. 3(2):43–47. [PMC free article] [PubMed]
14. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. 2004. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64:3878–3884. [PubMed]
15. Hartwell LH, Kastan MB. 1994. Cell cycle control and cancer. Science 266:1821–1828. [PubMed]
16. Lanni JS, Jacks T. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18:1055–1064. [PMC free article] [PubMed]
17. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. [PubMed]
18. Stewart ZA, Pietenpol JA. 2001. p53 signaling and cell cycle checkpoints. Chem. Res. Toxicol. 14:243–263. [PubMed]
19. Helt AM, Galloway DA. 2001. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75:6737–6747. [PMC free article] [PubMed]
20. Damelin M, Bestor TH. 2007. The decatenation checkpoint. Br. J. Cancer 96:201–205. [PMC free article] [PubMed]
21. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57:727–741. [PubMed]
22. Polager S, Ginsberg D. 2003. E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress. J. Biol. Chem. 278:1443–1449. [PubMed]
23. Thompson DA, Belinsky G, Chang TH, Jones DL, Schlegel R, Munger K. 1997. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 15:3025–3035. [PubMed]
24. Spardy N, Covella K, Cha E, Hoskins EE, Wells SI, Duensing A, Duensing S. 2009. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 69:7022–7029. [PMC free article] [PubMed]
25. Heilman SA, Nordberg JJ, Liu Y, Sluder G, Chen JJ. 2009. Abrogation of the postmitotic checkpoint contributes to polyploidization in human papillomavirus E7-expressing cells. J. Virol. 83:2756–2764. [PMC free article] [PubMed]
26. Liu Y, Heilman SA, Illanes D, Sluder G, Chen JJ. 2007. p53-independent abrogation of a postmitotic checkpoint contributes to HPV E6-induced polyploidy. Cancer Res. 67:2603–2610. [PubMed]
27. Berger KL, Barriga F, Lace MJ, Turek LP, Zamba GJ, Domann FE, Lee JH, Klingelhutz AJ. 2006. Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras. Virology 356:68–78. [PMC free article] [PubMed]
28. Ballabeni A, Melixetian M, Zamponi R, Masiero L, Marinoni F, Helin K. 2004. Human geminin promotes pre-RC formation and DNA replication by stabilizing CDT1 in mitosis. EMBO J. 23:3122–3132. [PubMed]
29. Nevis KR, Cordeiro-Stone M, Cook JG. 2009. Origin licensing and p53 status regulate Cdk2 activity during G(1). Cell Cycle 8:1952–1963. [PMC free article] [PubMed]
30. Chen J, Stubbe J. 2005. Bleomycins: towards better therapeutics. Nat. Rev. 5:102–112. [PubMed]
31. Banerjee NS, Wang HK, Broker TR, Chow LT. 2011. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J. Biol. Chem. 286:15473–15482. [PubMed]
32. Duensing S, Munger K. 2002. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 62:7075–7082. [PubMed]
33. Rogoff HA, Pickering MT, Frame FM, Debatis ME, Sanchez Y, Jones S, Kowalik TF. 2004. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol. Cell. Biol. 24:2968–2977. [PMC free article] [PubMed]
34. Lindahl T. 1993. Instability and decay of the primary structure of DNA. Nature 362:709–715. [PubMed]
35. Goto H, Tomono Y, Ajiro K, Kosako H, Fujita M, Sakurai M, Okawa K, Iwamatsu A, Okigaki T, Takahashi T, Inagaki M. 1999. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J. Biol. Chem. 274:25543–25549. [PubMed]
36. Dunphy WG, Kumagai A. 1991. The cdc25 protein contains an intrinsic phosphatase activity. Cell 67:189–196. [PubMed]
37. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW. 1991. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67:197–211. [PubMed]
38. Strausfeld U, Labbe JC, Fesquet D, Cavadore JC, Picard A, Sadhu K, Russell P, Doree M. 1991. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351:242–245. [PubMed]
39. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. 1997. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501–1505. [PubMed]
40. Hutchins JR, Clarke PR. 2004. Many fingers on the mitotic trigger: post-translational regulation of the Cdc25C phosphatase. Cell Cycle 3:41–45. [PubMed]
41. Machida YJ, Dutta A. 2007. The APC/C inhibitor, Emi1, is essential for prevention of rereplication. Genes Dev. 21:184–194. [PubMed]
42. Mihaylov IS, Kondo T, Jones L, Ryzhikov S, Tanaka J, Zheng J, Higa LA, Minamino N, Cooley L, Zhang H. 2002. Control of DNA replication and chromosome ploidy by geminin and cyclin A. Mol. Cell. Biol. 22:1868–1880. [PMC free article] [PubMed]
43. Nishitani H, Sugimoto N, Roukos V, Nakanishi Y, Saijo M, Obuse C, Tsurimoto T, Nakayama KI, Nakayama K, Fujita M, Lygerou Z, Nishimoto T. 2006. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J. 25:1126–1136. [PubMed]
44. Yoshida K, Inoue I. 2004. Regulation of geminin and Cdt1 expression by E2F transcription factors. Oncogene 23:3802–3812. [PubMed]
45. Demers GW, Foster SA, Halbert CL, Galloway DA. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. U. S. A. 91:4382–4386. [PubMed]
46. Hickman ES, Picksley SM, Vousden KH. 1994. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:2177–2181. [PubMed]
47. Slebos RJC, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 91:5320–5324. [PubMed]
48. Davy CE, Jackson DJ, Raj K, Peh WL, Southern SA, Das P, Sorathia R, Laskey P, Middleton K, Nakahara T, Wang Q, Masterson PJ, Lambert PF, Cuthill S, Millar JB, Doorbar J. 2005. Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes. J. Virol. 79:3998–4011. [PMC free article] [PubMed]
49. Davy C, Doorbar J. 2007. G2/M cell cycle arrest in the life cycle of viruses. Virology 368:219–226. [PubMed]
50. Li G, Park HU, Liang D, Zhao RY. 2010. Cell cycle G2/M arrest through an S phase-dependent mechanism by HIV-1 viral protein R. Retrovirology 7:59. [PMC free article] [PubMed]
51. Higa LA, Banks D, Wu M, Kobayashi R, Sun H, Zhang H. 2006. L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle 5:1675–1680. [PubMed]
52. Jin J, Arias EE, Chen J, Harper JW, Walter JC. 2006. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell 23:709–721. [PubMed]
53. Li X, Zhao Q, Liao R, Sun P, Wu X. 2003. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J. Biol. Chem. 278:30854–30858. [PubMed]
54. Sugimoto N, Kitabayashi I, Osano S, Tatsumi Y, Yugawa T, Narisawa-Saito M, Matsukage A, Kiyono T, Fujita M. 2008. Identification of novel human Cdt1-binding proteins by a proteomics approach: proteolytic regulation by APC/CCdh1. Mol. Biol. Cell 19:1007–1021. [PMC free article] [PubMed]
55. Patel D, McCance DJ. 2010. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. J. Virol. 84:10956–10964. [PMC free article] [PubMed]
56. Dowen SE, Scott A, Mukherjee G, Stanley MA. 2003. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int. J. Cancer 105:326–330. [PubMed]
57. Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, Bagchi S. 2004. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J. Virol. 78:5338–5346. [PMC free article] [PubMed]
58. Fujita M. 2006. Cdt1 revisited: complex and tight regulation during the cell cycle and consequences of deregulation in mammalian cells. Cell Div. 1:22. [PMC free article] [PubMed]
59. Sugimoto N, Tatsumi Y, Tsurumi T, Matsukage A, Kiyono T, Nishitani H, Fujita M. 2004. Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding. J. Biol. Chem. 279:19691–19697. [PubMed]
60. Fujita M, Yamada C, Tsurumi T, Hanaoka F, Matsuzawa K, Inagaki M. 1998. Cell cycle- and chromatin binding state-dependent phosphorylation of human MCM heterohexameric complexes. A role for cdc2 kinase. J. Biol. Chem. 273:17095–17101. [PubMed]
61. Itzhaki JE, Gilbert CS, Porter AC. 1997. Construction by gene targeting in human cells of a “conditional” CDC2 mutant that rereplicates its DNA. Nat. Genet. 15:258–265. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)